Keywords
Incidence
Herpes simplex virus
Lymphadenopathy
Diosmine-herperidin
Rash
Corticosteroids
IgM
How to Cite
Abstract
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe cutaneous adverse reaction. The incidence is 1-1,000,000 with a mortality rate of 3.8-10%, and it is a disease associated with reactivation of the herpes simplex virus.
Case report: A 34-year-old woman with atopy and venous insufficiency presented with pruritic hives on her face and arms, which progressed to a morbilliform rash, facial edema, fever, lymphadenopathy, and scaling. A complete blood count showed no abnormalities: AST: 837 U/L, ALT: 11352 U/L. Due to the suspicion of DRESS syndrome, treatment with corticosteroids was initiated and a biopsy was obtained. Upon questioning, the patient reported having taken diosmin-hesperidin and undergone systemic sunscreen (Heliocare360°®) 21 days prior to the onset of the rash. Histopathological examination revealed atrophic epidermis, vacuolar degeneration, and inflammatory infiltrate. Systemic corticosteroids were administered for three weeks, with a satisfactory response. Two months later, the patient experienced reactivation of the dermatosis and hypertransaminasemia; the autoantibody panel and serology were positive for IgM for herpes simplex virus.
Conclusion: This case underscores the need to consider severe hypersensitivity reactions, even with commonly used and apparently low-risk drugs. The importance of a comprehensive approach, including identification of the suspected medication, exclusion of differential diagnoses, prolonged clinical follow-up, and surveillance for possible viral reactivation, is emphasized.
Keywords: DRESS syndrome; Incidence; Herpes simplex virus; Lymphadenopathy; Diosmine-herperidin; Rash; Corticosteroids; IgM.
References
1. Hama N, Abe R, Gibson A, Phillips EJ. Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis. Journal of Allergy and Clinical Immunology: In Practice 2022 1; 10 (5): 1155-1167.e5.
2. Calle AM, Aguirre N, Ardila JC, Cardona-Villa R. DRESS syndrome: A literature review and treatment algorithm. Vol. 16, World Allergy Organization J Elsevier Inc; 2023.
3. Ramirez GA, Ripa M, Burastero S, Benanti G, Bagnasco D, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses. Microorganisms 2023; 11 (2): 346.
4. Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review. Eur J Drug Metab Pharmacokinet 2022; 47 (1): 1-18.
5. Segars K, McCarver V, Miller RA. Dermatologic Applications of Polypodium leucotomos: A Literature Review. J Clin Aesthet Dermatol 2021; 14 (2): 50-60. http://www.ncbi.nlm.nih.gov/pubmed/34221229
6. Pavón-Romero GF, Gutiérrez-Quiroz KV, Ramírez-Jiménez F, Rosas-Fernández R, et al. DRESS, una reacción alérgica no mediada por IgE. Rev Fac Med 2023 10; 66 (2): 7-19.
7. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169 (5): 1071-80.
8. Awad N, Hetzel JD, Bhupalam V, Nestor MS. Stasis Dermatitis: Pathophysiology, Current Treatment Paradigms, and the Use of the Flavonoid Diosmin. J Clin Aesthet Dermatol 2024; 17 (1): 15-23. http://www.ncbi.nlm.nih.gov/pubmed/38298753
9. Palakornkitti P, Rattananukrom T. Drug Reaction with Eosinophilia and Systemic Symptoms Induced by Diosmin and Hesperidin: A Case Report. Clinical, Cosmetic and Investigational Dermatology 2024; 17: 1127-32.
10. Barbaud A, Goncalo M, Mockenhaupt M, Copaescu A, et al. Delayed Skin Testing for Systemic Medications: Helpful or Not? J Allergy Clin Immunol Pract 2024; 12 (9): 2268-77.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Revista Alergia México